We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Targeted Drugs as Maintenance Therapy after Autologous Stem Cell Transplantation in Patients with Mantle Cell Lymphoma.
- Authors
Fengting Yan; Gopal, Ajay K.; Graf, Solomon A.
- Abstract
The treatment landscape for mantle cell lymphoma (MCL) is rapidly evolving toward the incorporation of novel and biologically targeted pharmaceuticals with improved disease activity and gentler toxicity profiles compared with conventional chemotherapeutics. Upfront intensive treatment of MCL includes autologous stem cell transplantation (SCT) consolidation aimed at deepening and lengthening disease remission, but subsequent relapse occurs. Maintenance therapy after autologous SCT in patients with MCL in remission features lower-intensity treatments given over extended periods to improve disease outcomes. Targeted drugs are a natural fit for this space, and are the focus of considerable clinical investigation. This review summarizes recent advances in the field and their potential impact on treatment practices for MCL.
- Subjects
MANTLE cell lymphoma; STEM cell transplantation; TOXICITY testing; DISEASE remission; CANCER chemotherapy; THERAPEUTICS
- Publication
Pharmaceuticals (14248247), 2017, Vol 10, Issue 1, p28
- ISSN
1424-8247
- Publication type
Article
- DOI
10.3390/ph10010028